Loading stock data…
$24.89+0.11 (+0.44%)
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States.
Baxter International Inc. in the Healthcare sector is trading at $24.89 with a market capitalization of $13.8B. Wall Street consensus targets $27.92 (12 analysts), implying a +12.2% move over the next 12 months. The stock is currently 17% below its 52-week high of $30.00, remaining 18.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.96B↑ | $2.70B↓ | $2.97B↑ | $2.83B↑ | $2.81B |
| Gross Profit | $1.03B↑ | $891.00M↑ | $577.00M↓ | $950.00M↓ | $991.00M |
| Operating Income | $217.00M↑ | $66.00M↑ | -$244.00M↓ | $172.00M↓ | $191.00M |
| Net Income | $126.00M↑ | -$15.00M↑ | -$1.13B↓ | -$46.00M↓ | $91.00M |
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. ...
Academic risk and quality models computed from BAX's own filings and price history, not from analyst opinion.
Mixed: 5 of 9 fundamental-health tests pass, so profitability and balance-sheet trends disagree.
Altman Z in the 1.81 to 2.99 grey zone, the band where the model gives no clear bankruptcy verdict.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
Hidden Markov model fitted to two years of returns, separating bull, bear and sideways states by their own drift and volatility.
GARCH(1,1) 30-day annualised forecast, above the current 40.0% reading.
Fama-French 5-factor market beta. The five factors explain 32% of this stock's return variance; the rest is idiosyncratic.
Model inputs as of 2026-10-13.